Loading…
Reported covered position: Chief Domestic Policy Council - Sen. Ron Wyden
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2026 · third_quarter · Q3
Intellectual Property Reform concerning bio-pharmaceutical industry
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose conbination drugs and general research and development Prescription Information Modernization Act of 2026 (PIMA)
Source: Senate LDA
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose conbination drugs and general research and development Prescription Information Modernization Act of 2026 (PIMA)
Protecting Patient Access to Cancer and Complex Therapies Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions
Protecting Patient Access to Cancer and Complex Therapies Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose conbination drugs and general research and development Prescription Information Modernization Act of 2026 (PIMA)
Protecting Patient Access to Cancer and Complex Therapies Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose conbination drugs and general research and development Prescription Information Modernization Act of 2026 (PIMA)
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions
Community Health Center Drug Pricing Protection Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act
Community Health Center Drug Pricing Protection Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions Biosimilars reimbursement issues H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.1968, lobbied for passage of the Continuing Resolution to include PBM reform
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions Biosimilars reimbursement issues H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.1968, lobbied for passage of the Continuing Resolution to include PBM reform
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025
Full-Year Continuing Appropriations and Extensions Act, 2025
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Full-Year Continuing Appropriations and Extensions Act, 2025
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions Biosimilars reimbursement issues H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.1968, lobbied for passage of the Continuing Resolution to include PBM reform
Full-Year Continuing Appropriations and Extensions Act, 2025
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Student Loan Marriage Penalty Elimination Act of 2025
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Student Loan Marriage Penalty Elimination Act of 2025
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Clinical Trial Modernization Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Clinical Trial Modernization Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Protecting Patient Access to Cancer and Complex Therapies Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025
Protecting Patient Access to Cancer and Complex Therapies Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions Biosimilars reimbursement issues H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.1968, lobbied for passage of the Continuing Resolution to include PBM reform
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act
Stop CCP Money Laundering Act of 2025
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Stop CCP Money Laundering Act of 2025
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Pharmacy Benefit Manager Transparency Act of 2025
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Pharmacy Benefit Manager Transparency Act of 2025
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Facilitating DIGITAL Applications Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act
Lower Costs, More Transparency Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act
Clinical Trial Modernization Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act
Pharmacy Benefit Manager Transparency Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act
Pharmacy Benefit Manager Reform Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act
Modernizing and Ensuring PBM Accountability Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act
For the People Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions
Methane Waste Prevention Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions
To provide for a limitation on availability of funds for Executive Office of the President, Office of National Drug Control Policy, Salaries and Expenses for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation H.R.7625, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
To provide for a limitation on availability of funds for Executive Office of the President, Office of National Drug Control Policy, Salaries and Expenses for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
To provide for a limitation on availability of funds for U.S. Department of Interior, US Fish and Wildlife Service, Multinational Species Conservation Fund for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
To provide for a limitation on availability of funds for U.S. Department of Interior, US Fish and Wildlife Service, Multinational Species Conservation Fund for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
To provide for a limitation on availability of funds for U.S. Department of Interior, US Fish and Wildlife Service, Multinational Species Conservation Fund for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation H.R.7625, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
To provide for a limitation on availability of funds for U.S. Department of Interior, US Fish and Wildlife Service, Multinational Species Conservation Fund for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
Protecting Patients Against PBM Abuses Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act H.R.6283, 118th Congress: DRUG Act H.R.2880, Protecting Patients Against PBM Abuses Act
Facilitating DIGITAL Applications Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act Modernizing and Ensuring Equity Act
Facilitating DIGITAL Applications Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act
Facilitating DIGITAL Applications Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act H.R.9747, Continuing Appropriations and Extensions Act
Facilitating DIGITAL Applications Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act H.R.6283, 118th Congress: DRUG Act H.R.2880, Protecting Patients Against PBM Abuses Act
PATIENT Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding health equity H.R.830, HELP Copays Act of 2023 H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Biosimilars reimbursement issues International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act
Lowering Drug Costs for American Families Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding health equity H.R.830, HELP Copays Act of 2023 H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Biosimilars reimbursement issues International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act
Lower Costs, More Transparency Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act H.R.6283, 118th Congress: DRUG Act H.R.2880, Protecting Patients Against PBM Abuses Act
Lower Costs, More Transparency Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act H.R.9747, Continuing Appropriations and Extensions Act
Lower Costs, More Transparency Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act Modernizing and Ensuring Equity Act
Lower Costs, More Transparency Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act
S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act H.R.6283, 118th Congress: DRUG Act H.R.2880, Protecting Patients Against PBM Abuses Act
RESPOND Act of 2024
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation H.R.7625, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
The 340B PATIENTS Act of 2024
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
The 340B PATIENTS Act of 2024
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
The 340B PATIENTS Act of 2024
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act H.R.9747, Continuing Appropriations and Extensions Act
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act Modernizing and Ensuring Equity Act
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act
Discussions regarding health equity H.R.830, HELP Copays Act of 2023 H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Biosimilars reimbursement issues International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act
Clinical Trial Modernization Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act H.R.9747, Continuing Appropriations and Extensions Act
Continuing Appropriations and Extensions Act, 2025
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act H.R.9747, Continuing Appropriations and Extensions Act
Pharmacy Benefit Manager Transparency Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act
Pharmacy Benefit Manager Transparency Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act H.R.6283, 118th Congress: DRUG Act H.R.2880, Protecting Patients Against PBM Abuses Act
Pharmacy Benefit Manager Transparency Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act Modernizing and Ensuring Equity Act
Pharmacy Benefit Manager Transparency Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act H.R.9747, Continuing Appropriations and Extensions Act
Pharmacy Benefit Manager Reform Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act H.R.9747, Continuing Appropriations and Extensions Act
Pharmacy Benefit Manager Reform Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act
Pharmacy Benefit Manager Reform Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act Modernizing and Ensuring Equity Act
Pharmacy Benefit Manager Reform Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act H.R.6283, 118th Congress: DRUG Act H.R.2880, Protecting Patients Against PBM Abuses Act
Modernizing and Ensuring PBM Accountability Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act
Modernizing and Ensuring PBM Accountability Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act H.R.6283, 118th Congress: DRUG Act H.R.2880, Protecting Patients Against PBM Abuses Act
Modernizing and Ensuring PBM Accountability Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act H.R.9747, Continuing Appropriations and Extensions Act
Extending Temporary Emergency Scheduling of Fentanyl Analogues Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathway Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act Mental health issues Biosimilars reimbursement issues
Extending Temporary Emergency Scheduling of Fentanyl Analogues Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act
Freedom to Haul Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathway Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act Mental health issues Biosimilars reimbursement issues
Freedom to Haul Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act
Moving and Fostering Innovation to Revolutionize Smarter Transportation Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathway Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act Mental health issues Biosimilars reimbursement issues
Moving and Fostering Innovation to Revolutionize Smarter Transportation Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act
Access to Innovative Treatments Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Access to Innovative Treatments Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Protecting Patients Against PBM Abuses Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Protecting Patients Against PBM Abuses Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
PATIENT Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
PATIENT Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Protecting Health Care for All Patients Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Protecting Health Care for All Patients Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Protecting Health Care for All Patients Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Protecting Health Care for All Patients Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Lowering Drug Costs for American Families Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Lowering Drug Costs for American Families Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Share the Savings with Seniors Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Share the Savings with Seniors Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Share the Savings with Seniors Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues Issues concerning competitive trade
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2026 · second_quarter · Q2
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions
Intellectual Property Reform concerning bio-pharmaceutical industry
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation
International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues Issues concerning competitive trade
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2026 · first_quarter · Q1
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation
Intellectual Property Reform concerning bio-pharmaceutical industry
International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2025 · fourth_quarter · Q4
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025
Intellectual Property Reform concerning bio-pharmaceutical industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2025 · third_quarter · Q3
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions Biosimilars reimbursement issues H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.1968, lobbied for passage of the Continuing Resolution to include PBM reform
Intellectual Property Reform concerning bio-pharmaceutical industry
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2025 · second_quarter · Q2
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Issues related to the six protected classes of medicines under Medicare Part D, regarding all bio-pharmaceutical issues
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2025 · first_quarter · Q1
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act ORPHAN Act Mental Health Appropriations Language FY26
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2024 · fourth_quarter · Q4
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act H.R.9747, Continuing Appropriations and Extensions Act
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2024 · third_quarter · Q3
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathway Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act Mental health issues Biosimilars reimbursement issues
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions OECD Implementation
Intellectual Property Reform concerning bio-pharmaceutical industry
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2024 · second_quarter · Q2
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions OECD Implementation
Intellectual Property Reform concerning bio-pharmaceutical industry
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2024 · first_quarter · Q1
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation H.R.7625, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
Intellectual Property Reform concerning bio-pharmaceutical industry Trade-Related aspects of Intellectual Property (TRIPS) Waiver
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2023 · fourth_quarter · Q4
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2023 · third_quarter · Q3
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2023 · second_quarter · Q2
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2023 · first_quarter · Q1
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2022 · fourth_quarter · Q4
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions Discussions regarding HR 3173, Improving Seniors' Timely Access to Care Act PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2022 · third_quarter · Q3
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2022 · second_quarter · Q2
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity S 4293, Pharmacy Benefit Manager Transparency Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2022 · first_quarter · Q1
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464 - Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues Related to the Food and Drug Administration's accelerated approval process - regarding all bio-pharmaceutical related provisions. No bill number. H.R 4385 - Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. E- Prescribing Information- regarding modernizing the distribution of prescribing information. No bill number Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2021 · first_quarter · 1A
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes -regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2021 · fourth_quarter · Q4
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions. No bill number.
H.R. 2163 - To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purpose - regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purpose - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. H.R 4385 - Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act - Establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health - regarding all bio-pharmaceutical related provisions H.R. 19 - Lower Cost, More Cures Act of 2021 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purpose - regarding all bio-pharmaceutical related provisions H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376 the Build Back Better Act - regarding all bio-pharmaceutical related provision.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2021 · third_quarter · Q3
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
H.R. 2163 - To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. H.R 4385 - Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act - Establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health regarding all bio-pharmaceutical related provisions H.R. 19 - Lower Cost, More Cures Act of 2021 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes regarding all bio-pharmaceutical related provisions H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2021 · second_quarter · Q2
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1435/H.R. 2873 - Affordable Prescriptions for Patients Act of 2021 - prohibition on product hopping
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2021 · first_quarter · Q1
H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · third_quarter · 3A
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · second_quarter · 2A
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · fourth_quarter · 4A
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Most Favored Nation (MFN) Model - (CMS-5528-IFC)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · fourth_quarter · Q4
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · third_quarter · Q3
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · second_quarter · Q2
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
Intellectual Property Reform concerning bio-pharmaceutical industry
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual Property Reform concerning bio-pharmaceutical industry
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Intellectual Property Reform concerning bio-pharmaceutical industry Discussions regarding the Patent Eligibility Restoration Act
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act Biosimilars reimbursement issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act Modernizing and Ensuring Equity Act
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding health equity H.R.830, HELP Copays Act of 2023 H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Biosimilars reimbursement issues International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions OECD Implementation
S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act H.R.6283, 118th Congress: DRUG Act H.R.2880, Protecting Patients Against PBM Abuses Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions and corporate tax provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number.
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1435/H.R. 2873 - Affordable Prescriptions for Patients Act of 2021 - prohibition on product hopping
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1435/H.R. 2873 - Affordable Prescriptions for Patients Act of 2021 - prohibition on product hopping
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. H.R 4385 - Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act - Establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health regarding all bio-pharmaceutical related provisions H.R. 19 Lower Cost, More Cures Act of 2021 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes -regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions H.R. 133, the Consolidated Appropriations Act of 2021, regarding all bio-pharmaceutical related provisions
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Most Favored Nation (MFN) Model - (CMS-5528-IFC)
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions H.R. 133, the Consolidated Appropriations Act of 2021, regarding all bio-pharmaceutical related provisions
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)